Anakinra, a recombinant human IL-1 receptor antagonist, in clinical practice. Outcome in 60 patients with severe rheumatoid arthritis
Objective: We evaluated both the efficacy and safety of anakinra in daily routine rheumatoid arthritis clinical practice. Methods:We studied 60 cases, including patients with previous anti-TNFα exposure, treated with anakinra (100 mg/daily s.c.) in combination with methotrexate (7.5-10 mg/week i.m.)...
| Main Authors: | , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
PAGEPress Publications
2011-09-01
|
| Series: | Reumatismo |
| Online Access: | http://www.reumatismo.org/index.php/reuma/article/view/293 |
| _version_ | 1811291814263521280 |
|---|---|
| author | S. Todesco U. Fiocco M. Biscaro P. Ostuni A. Furlan P. Sfriso C. Botsios L. Punzi |
| author_facet | S. Todesco U. Fiocco M. Biscaro P. Ostuni A. Furlan P. Sfriso C. Botsios L. Punzi |
| author_sort | S. Todesco |
| collection | DOAJ |
| description | Objective: We evaluated both the efficacy and safety of anakinra in daily routine rheumatoid arthritis clinical practice. Methods:We studied 60 cases, including patients with previous anti-TNFα exposure, treated with anakinra (100 mg/daily s.c.) in combination with methotrexate (7.5-10 mg/week i.m.) or leflunomide (20 mg/die) in a two year observational study. Efficacy measures were assessed using the American College of Rheumatology (ACR) response criteria. Safety was evaluated according to a modified World Health Organization adverse reaction term dictionary. Results: At week 14, ACR 20% response criteria have been fulfilled by 53 (91.3%) out of 58 patients, 51 (87.9%) of them achieving also an ACR 50%and 15 (25.8%) an ACR 70%response. Thirteen patients touched 102 weeks of treatment: ACR 20% response was achieved in 92.3%, while ACR 50% and ACR 70% were respectively found in 84.6% and 38.4% of the cases. The mean decrease in HAQ score was 0.38, p<0.001. Of the 16 patients who were previously treated with anti-TNFα blockers, 81.2% responded to anakinra. There was no significant difference in the ACR response between groups with and without previous anti-TNFα exposure. Seventeen patients (28.3%) stopped anakinra because of side-effects (5%) or failure to respond (23.3%). Only 4 cases of pulmonitis, of which 2 have been hospitalised, and 1 case with tuberculosis (previously treated with infliximab) were observed. Conclusions: Our clinical experience confirms that anakinra is effective and safe in the treatment of rheumatoid arthritis. Anakinra seems also useful in patients with previous anti-TNFα blockers failures. Even though major adverse events were rare, clinicians should be aware of such a possibility |
| first_indexed | 2024-04-13T04:35:04Z |
| format | Article |
| id | doaj.art-5d0e3d11f15e4cd88cdf87bb19fe026f |
| institution | Directory Open Access Journal |
| issn | 0048-7449 2240-2683 |
| language | English |
| last_indexed | 2024-04-13T04:35:04Z |
| publishDate | 2011-09-01 |
| publisher | PAGEPress Publications |
| record_format | Article |
| series | Reumatismo |
| spelling | doaj.art-5d0e3d11f15e4cd88cdf87bb19fe026f2022-12-22T03:02:11ZengPAGEPress PublicationsReumatismo0048-74492240-26832011-09-01591323710.4081/reumatismo.2007.32Anakinra, a recombinant human IL-1 receptor antagonist, in clinical practice. Outcome in 60 patients with severe rheumatoid arthritisS. TodescoU. FioccoM. BiscaroP. OstuniA. FurlanP. SfrisoC. BotsiosL. PunziObjective: We evaluated both the efficacy and safety of anakinra in daily routine rheumatoid arthritis clinical practice. Methods:We studied 60 cases, including patients with previous anti-TNFα exposure, treated with anakinra (100 mg/daily s.c.) in combination with methotrexate (7.5-10 mg/week i.m.) or leflunomide (20 mg/die) in a two year observational study. Efficacy measures were assessed using the American College of Rheumatology (ACR) response criteria. Safety was evaluated according to a modified World Health Organization adverse reaction term dictionary. Results: At week 14, ACR 20% response criteria have been fulfilled by 53 (91.3%) out of 58 patients, 51 (87.9%) of them achieving also an ACR 50%and 15 (25.8%) an ACR 70%response. Thirteen patients touched 102 weeks of treatment: ACR 20% response was achieved in 92.3%, while ACR 50% and ACR 70% were respectively found in 84.6% and 38.4% of the cases. The mean decrease in HAQ score was 0.38, p<0.001. Of the 16 patients who were previously treated with anti-TNFα blockers, 81.2% responded to anakinra. There was no significant difference in the ACR response between groups with and without previous anti-TNFα exposure. Seventeen patients (28.3%) stopped anakinra because of side-effects (5%) or failure to respond (23.3%). Only 4 cases of pulmonitis, of which 2 have been hospitalised, and 1 case with tuberculosis (previously treated with infliximab) were observed. Conclusions: Our clinical experience confirms that anakinra is effective and safe in the treatment of rheumatoid arthritis. Anakinra seems also useful in patients with previous anti-TNFα blockers failures. Even though major adverse events were rare, clinicians should be aware of such a possibilityhttp://www.reumatismo.org/index.php/reuma/article/view/293 |
| spellingShingle | S. Todesco U. Fiocco M. Biscaro P. Ostuni A. Furlan P. Sfriso C. Botsios L. Punzi Anakinra, a recombinant human IL-1 receptor antagonist, in clinical practice. Outcome in 60 patients with severe rheumatoid arthritis Reumatismo |
| title | Anakinra, a recombinant human IL-1 receptor antagonist, in clinical practice. Outcome in 60 patients with severe rheumatoid arthritis |
| title_full | Anakinra, a recombinant human IL-1 receptor antagonist, in clinical practice. Outcome in 60 patients with severe rheumatoid arthritis |
| title_fullStr | Anakinra, a recombinant human IL-1 receptor antagonist, in clinical practice. Outcome in 60 patients with severe rheumatoid arthritis |
| title_full_unstemmed | Anakinra, a recombinant human IL-1 receptor antagonist, in clinical practice. Outcome in 60 patients with severe rheumatoid arthritis |
| title_short | Anakinra, a recombinant human IL-1 receptor antagonist, in clinical practice. Outcome in 60 patients with severe rheumatoid arthritis |
| title_sort | anakinra a recombinant human il 1 receptor antagonist in clinical practice outcome in 60 patients with severe rheumatoid arthritis |
| url | http://www.reumatismo.org/index.php/reuma/article/view/293 |
| work_keys_str_mv | AT stodesco anakinraarecombinanthumanil1receptorantagonistinclinicalpracticeoutcomein60patientswithsevererheumatoidarthritis AT ufiocco anakinraarecombinanthumanil1receptorantagonistinclinicalpracticeoutcomein60patientswithsevererheumatoidarthritis AT mbiscaro anakinraarecombinanthumanil1receptorantagonistinclinicalpracticeoutcomein60patientswithsevererheumatoidarthritis AT postuni anakinraarecombinanthumanil1receptorantagonistinclinicalpracticeoutcomein60patientswithsevererheumatoidarthritis AT afurlan anakinraarecombinanthumanil1receptorantagonistinclinicalpracticeoutcomein60patientswithsevererheumatoidarthritis AT psfriso anakinraarecombinanthumanil1receptorantagonistinclinicalpracticeoutcomein60patientswithsevererheumatoidarthritis AT cbotsios anakinraarecombinanthumanil1receptorantagonistinclinicalpracticeoutcomein60patientswithsevererheumatoidarthritis AT lpunzi anakinraarecombinanthumanil1receptorantagonistinclinicalpracticeoutcomein60patientswithsevererheumatoidarthritis |